SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Paratek Pharmaceuticals, Inc. (PRTK)

PRTK RSS Feed
Add PRTK Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 9/4/2016 2:24:02 PM - Followers: 2 - Board type: Free - Posts Today: 0

Paratek Pharmaceuticals, Inc. 75 Park Plaza Boston, MA 02116 United States 617-807-6600 http://www.paratekpharm.com Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include Omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PRTK
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PRTK News: Paratek Pharmaceuticals to Report First Quarter 2017 Financial Results and Provide Update on Clinical Progress on May 4, 2017... 07:00 AM
PRTK News: Omadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial Lining Fluid According to Pharmacokinetic/Pharm... 04/25/2017 07:30:00 AM
PRTK News: Current Report Filing (8-k) 04/24/2017 07:16:27 AM
PRTK News: New Health Economics Studies Highlight the Potential for Paratek Pharmaceuticals’ Omadacycline to Provide Cost-Savings Comp... 04/24/2017 07:00:00 AM
PRTK News: New Microbiology Data from Paratek Pharmaceuticals Show Omadacycline Effective Against Most Common Skin Infections and Pathog... 04/24/2017 07:00:00 AM
News News Alert: Paratek Pharmaceuticals to Report First Quarter 2017 Financial Results and Provide Update on Clinical Progress on May 4, 2017... 04/26/2017 07:00:00 AM
PostSubject
#2   PRTK bullish 13.61 stocktrademan 09/04/16 02:24:02 PM
#1   PRTK bearish 13.38 stocktrademan 07/16/16 12:39:44 PM
PostSubject